← All indications
Shock, Hemorrhagic
Acute hemorrhage or excessive fluid loss resulting in HYPOVOLEMIA.
Drugs by status
Phase 4 trials (1)
Phase 3 trials (11)
Phase 2 trials (4)
Phase 1 trials (1)
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (24)
- Innogene Kalbiotech Pte. Ltd
- Northfield Laboratories
- National Heart, Lung, and Blood Institute (NHLBI)
- Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
- University of Pittsburgh
- French Defence Health Service
- Medical University Innsbruck
- Virginia Commonwealth University
- University of California, Irvine
- Fire Brigade Of Paris
- Department of Defense
- Institut de Recherche Biomedicale des Armees
- CHU Henri Mondor
- Padjadjaran University
- University of Lyon
- University of Paris
- Grenoble Alps University
- Bataillon des marins pompiers de Marseille, France
- French Military
- Samu of Lyon, France
- Hospital center of Annecy Genevois,France
- Aix-University of Marseille
- Samu of Annecy, France
- University of Grenoble
Organization Involved with Phase 2 Indications (15)
- Sangart
- Neptunus Pharmaceuticals Inc.
- United States Army
- Aarhus University
- University of London
- University of Washington
- Oregon Health and Science University
- University of Oslo
- University of Southern Denmark
- Aalborg University
- Assiut University
- University of Colorado, Denver
- University of Copenhagen
- University of Colorado
- The University of Texas, Dallas
Organization Involved with Phase 1 Indications (1)
Organization Involved with Other Experimental Indications (2)